Verteporfin (Visudyne)
Defines medical necessity criteria, initial and continued therapy coverage, dosing limits, approved indications (predominantly classic subfoveal CNV due to AMD, presumed ocular histoplasmosis, pathologic myopia), off-label central serous chorioretinopathy criteria, exclusions, required documentation, approval durations, and coding implications for Verteporfin (Visudyne) under Centene lines of business (Commercial, HIM, Medicaid).
1Q 2025 annual review: for CNV due to pathologic myopia, revised failure of Avastin or Lucentis to bevacizumab and ranibizumab; Appendix B additions and references updated.
1Q 2023 annual review: updated commercial length of benefit to '12 months or duration of request, whichever is less'.
Ad Hoc converted redirection language from 'must use' to 'Failure of bevacizumab intravitreal solution'.
Added HIM line of business and reference updates in 1Q2021 annual review.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.